Medical News

RSS

Pendant style help button alerts users of potential risks

Philips Lifeline is issuing an important safety notice to its more than 750,000 subscribers of its personal emergency response service to alert users of potential risks with wearing a "pendant" style help button. The service is used primarily by seniors living independently in their homes who feel they are at risk of falls. By pressing a "help button" worn on the body, users connect to a remote monitoring center, staffed 24 hours a day, that can send emergency assistance to the user's home.

14 Sep 2009

Special Projects Discovery Grant program launched for brain tumor diagnosis research

The American Brain Tumor Association has launched a new Special Projects Discovery Grant program to support fresh and creative research ideas for solving the challenges of brain tumor diagnosis and treatment.

14 Sep 2009

Urodynamix Technologies raises funds through private placement

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it is raising a minimum of $1,500,000 through the issuance of 30,000,000 common shares of the Company at a price of $0.05 per common share. BC Advantage Funds has provided the Company with a lead order of $750,000.

14 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

InfraReDx to display Lipiscan at TCT scientific meeting

InfraReDx today announced its preliminary schedule of events at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from Monday, September 21st to Friday, September 25th, in San Francisco, CA. at the Moscone Center.

14 Sep 2009

Clinical study results of DAS181 against H1N1 influenza presented

NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA.

14 Sep 2009

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Teva Pharmaceutical Industries Ltd. and Active Biotech today presented data further illuminating the novel, dual mechanism of action (MOA) of investigational oral, once-daily, laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), conferring neuroprotective and anti-inflammatory properties.

14 Sep 2009

Phase IIa trial results of panobacumab released

Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The compound, a fully human IgM monoclonal antibody, has the potential to reduce mortality rates.

14 Sep 2009

Chemists develop two-minute water quality monitoring method

Space is not a fun place to get a stomach bug. To ensure drinking water is adequately disinfected, University of Utah chemists developed a two-minute water quality monitoring method that just started six months of tests aboard the International Space Station.

14 Sep 2009

HRSA receives funds to train health care professionals

HHS Secretary Kathleen Sebelius today announced awards totaling $33 million to expand the training of health care professionals. The funds are part of the $500 million allotted to HHS’ Health Resources and Services Administration (HRSA) to address workforce shortages under the American Recovery and Reinvestment Act (ARRA).

14 Sep 2009

IFG urges small business owners to concentrate on accounts receivable factoring

The Interface Financial Group (IFG), North America's largest alternative funding source for small business, suggests that until the nation's health care reform has been resolved, small business owners look to accounts receivable factoring. Small businesses are the engine of the economy, creating at least seventy percent of all new jobs, In the United States small businesses employ more than half of all private sector employees, pay 44 percent of total U.S. private payroll and have generated 64 percent of net new jobs over the past 15 years.

14 Sep 2009

Naproxcinod clinical study results presented at the 2009 World Congress on Osteoarthritis

NicOx S.A. today announced that it has made three scientific presentations at the 2009 World Congress on Osteoarthritis (annual congress of the Osteoarthritis Research Society International - OARSI), which was held from September 10 to 13 in Montreal, Canada.

14 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

First FOSAMAX case declared as mistrial by the U.S.District Court Judge

Merck & Co., Inc. said today that a mistrial was declared by U.S. District Court Judge John F. Keenan in Boles v. Merck, the first FOSAMAX case to go to trial. This case was the Plaintiffs’ Steering Committee's first choice to take to trial. The Boles case was tried in New York federal court and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX.

14 Sep 2009

Sectra reports increased sales and operating profit

IT and medical-technology company Sectra’s (STO:SECTB) net sales for the first quarter increased 13.7% to SEK 197.8 million (174.0) compared with the year-earlier period. Operating profit increased to SEK 10.1 million (0.9), corresponding to an operating margin of 5.1% (0.5) for the quarter. Profit after financial items amounted to SEK 3.5 million (6.2), corresponding to a profit margin of 1.8% (3.6). The Group’s order bookings amounted to SEK 152.1 million (175.2).

14 Sep 2009

New findings could yield effective therapies for multiple sclerosis

A Mayo Clinic study has found that two genes in mice were associated with good central nervous system repair in multiple sclerosis (MS). These findings give researchers new hope for developing more effective therapies for patients with MS and for predicting MS patients' outcomes.

14 Sep 2009

Results further support the benefits of TYSABRI for multiple sclerosis patients

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI- (natalizumab) experienced an improvement in both their physical function and psychological well-being.

14 Sep 2009

Recent releases: HIV and nutrition; new global health journal; male circumcision; Chagas disease; malaria research methods

"Despite calls from national and international organizations to integrate HIV and nutritional programs, data are lacking on how such programs can be effectively implemented in resource-poor settings, on the optimum content and duration of nutritional support, and on ideal target recipients," write the authors of a Clinical Infectious Diseases review that examines the relationship between HIV, nutritional deficiencies and food insecurity.

14 Sep 2009

Newly discovered molecular circuit helps maintain proper body metabolism

Researchers at the University of Pennsylvania School of Medicine have discovered a molecular circuit involving heme that helps maintain proper metabolism in the body, providing new insights into metabolic disorders such as obesity and diabetes.

14 Sep 2009

Prevention and treatment of pneumonia are critical to reducing child mortality

New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.

14 Sep 2009